11只科创板股大宗交易平台今日发生交易，合计成交1.48亿元。 科创板股8月18日大宗交易概况 证券时报·数据宝统计显示，8月18日共有11只科创板股发生大宗交易，合计成交13笔，累计成交量 254.23万股，成交额合计1.48亿元。 | 代码 | 简称 | 成交笔 | 大宗交易数量 | 平均成交价格 | 相对收盘价折溢价 | 大宗交易金额 | | --- | --- | --- | --- | --- | --- | --- | | | | 数 | （万股） | （元） | （%） | （万元） | | 688692 | 达梦数 | 2 | 15.91 | 234.47 | -6.40 | 3730.47 | | | 据 | | | | | | | 688080 | 映翰通 | 1 | 68.00 | 41.01 | -20.00 | 2788.68 | | 688166 | 博瑞医 药 | 1 | 25.00 | 100.62 | -10.00 | 2515.50 | | 688662 | 富信科 | 2 | 50.00 | 42.32 | | | | | 技 | | | | -13.40 | 2116. ...

两融数据显示，该股最新融资余额为25.18亿元，近5日增加2079.17万元，增幅为0.83%。（数据宝） 8月18日博瑞医药大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额 | 格 | 收盘折溢 | 买方营业部 | 卖方营业部 | | 股） | （万 | （元） | 价 | | | | | 元） | | （%） | | | | 25.00 | 2515.50 | 100.62 | -10.00 | 瑞银证券有限责任公司上海花园石桥路 | 国投证券股份有限公司江苏 | | | | | | 证券营业部 | 分公司 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （原标题：博瑞医药大宗交易成交25.00万股 成交额2515.50万元） 博瑞医药8月18日大宗交易平台出现一笔成交，成交量25.00万股，成交金额2515.50万元，大宗交易成交 价为100.62元，相对今日收盘价折价10.00%。该笔交易的买方营业部为瑞银证券有限责任公司上海花园 石桥路证券营业部，卖方营业部为国投 ...

| 2025-08-18 | 博瑞医药 | 688166 | 100.62 | 2515.5 | 25 | 瑞银证券有限责任 and a boom 3.8 d. wholes $11 .J. go | 国投证券股份有限 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 公司上海花园石桥 | 卖出营业部 公司江苏分公司 | 8月18日，博瑞医药大宗交易成交25万股，成交额2515.5万元，占当日总成交额的1.98%，成交价100.62元，较市场收盘价111.8元折价10%。 ...

Group 1 - The innovation drug concept remains active, with significant market movements and various sectors showing strong performance, particularly in the financial and innovation drug sectors [1] - The estimated market size for China's innovative drug and medical device market in 2024 is approximately 162 billion yuan, with predictions to exceed 1 trillion yuan by 2035 [1] - Multiple innovative drug ETFs have seen substantial inflows, with a total net inflow of 7.551 billion yuan in August, indicating strong investor interest [2] Group 2 - Over 80 innovative drug concept stocks have seen an average price increase of 4.42% since August, with some stocks like Nanmo Biology and Shunlian Bio rising over 40% [3] - Nanmo Biology has experienced the highest price increase of 97.5% in August, driven by its advanced technology platform for gene research [3] - Several innovative drug stocks, including Borui Pharmaceutical and Anke Bio, have received significant institutional attention, with over 10 institutions conducting research on them [4] Group 3 - Borui Pharmaceutical has signed a strategic cooperation agreement with Hanyu Pharmaceutical, enhancing its supply capabilities for future product launches [4] - Anke Bio has reached a nationwide exclusive agency agreement for a new innovative drug, which is expected to be the first long-acting follicle-stimulating hormone preparation in China [4] - More than half of the innovative drug concept stocks have received net buying from financing, with notable amounts for companies like WuXi AppTec and Borui Pharmaceutical [4]

Group 1 - The innovative drug concept remains active, with the market showing strong performance, as the Shanghai Composite Index surpassed 3731.69 points, a nearly 10-year high [1][3] - The innovative drug market in China is estimated to reach approximately 162 billion yuan in 2024, with a projected market size exceeding 1 trillion yuan by 2035 [3][4] - Multiple innovative drug ETFs have attracted significant capital inflow, with a total net inflow of 7.551 billion yuan in August alone [4] Group 2 - Over 80 innovative drug concept stocks have seen an average price increase of 4.42% since August, with notable performers like Nanmo Biology and Shunlian Bio rising over 40% [7] - Institutions have shown strong interest in several innovative drug stocks, with 90 institutions conducting research on Borui Pharmaceutical, which has signed a strategic cooperation agreement with Hanyu Pharmaceutical [7][10] - More than half of the innovative drug concept stocks have received net buying in financing since August, with major inflows seen in companies like WuXi AppTec and Borui Pharmaceutical [8]

- The report introduces a quantitative model named "250-day new high distance" to track market trends and identify hot sectors. The model calculates the distance of the latest closing price from the highest closing price in the past 250 trading days using the formula: $ 250\text{-day new high distance} = 1 - \frac{\text{Closet}}{\text{ts\_max(Close, 250)}} $ where Closet represents the latest closing price, and ts_max(Close, 250) is the maximum closing price over the past 250 trading days. If the latest closing price reaches a new high, the distance is 0; otherwise, it is a positive value indicating the degree of fallback [11][12][13] - The report evaluates the effectiveness of momentum and trend-following strategies, citing research that stocks near their 52-week highs tend to outperform those far from their highs. It references methodologies from George (2004), William O'Neil's CANSLIM system, and Mark Minervini's "Stock Market Wizard" to emphasize the importance of tracking stocks consistently hitting new highs [11][19][22] - A screening method for "stable new high stocks" is introduced, focusing on stocks with smooth price paths and sustained momentum. The criteria include analyst attention (minimum 5 buy or overweight ratings in the past 3 months), relative price strength (top 20% in 250-day returns), price path smoothness (evaluated by metrics like price displacement ratio), and trend persistence (average 250-day new high distance over the past 120 days and past 5 days). The top 50 stocks meeting these criteria are selected [26][29][30] - The report identifies 1480 stocks that hit 250-day new highs in the past 20 trading days. Among them, the mechanical, pharmaceutical, and basic chemical industries have the highest number of new high stocks, while steel, defense, and non-ferrous metals have the highest proportion of new high stocks. By index, the highest proportions are found in CSI 2000 (27.55%), CSI 1000 (23.50%), and CSI 500 (24.60%) [20][21][34] - The report highlights the distribution of stable new high stocks across sectors, with manufacturing and technology leading the count (16 and 15 stocks, respectively). Within manufacturing, the mechanical industry dominates, while electronics lead in the technology sector [30][34] - The quantitative model's backtesting results show that major indices like SSE Composite, SZSE Component, CSI 300, CSI 500, CSI 1000, CSI 2000, ChiNext, and STAR 50 have 250-day new high distances of 0.00%, 0.00%, 1.26%, 0.00%, 0.00%, 0.00%, 0.63%, and 2.27%, respectively. Industry indices such as pharmaceuticals, non-ferrous metals, basic chemicals, electronics, and light manufacturing are close to their 250-day highs, while food and beverage, coal, real estate, consumer services, and banking are far from their highs [12][13][33]

博瑞医药8月14日大宗交易平台共发生2笔成交，合计成交量13.00万股，成交金额1329.12万元。成交价 格均为102.24元，相对今日收盘价折价9.99%。从参与大宗交易营业部来看，机构专用席位共出现在1笔 成交的买方或卖方营业部中，合计成交金额为613.44万元，净买入613.44万元。 进一步统计，近3个月内该股累计发生21笔大宗交易，合计成交金额为2.04亿元。 证券时报·数据宝统计显示，博瑞医药今日收盘价为113.59元，上涨0.71%，日换手率为2.37%，成交额 为11.31亿元，全天主力资金净流入624.37万元，近5日该股累计上涨5.67%，近5日资金合计净流入1.06 亿元。 两融数据显示，该股最新融资余额为25.39亿元，近5日增加3.43亿元，增幅为15.61%。（数据宝） 8月14日博瑞医药大宗交易一览 | 成交量 | 成交金额 （万元） | 成交价格 | 相对当日收盘折 溢价（%） | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | | （元） | | | | | 7.00 | 715.68 | 102 ...

Company Overview - The stock price of Borui Pharmaceutical is reported at 112.79 yuan, down 0.67% from the previous trading day [1] - The stock reached a high of 116.19 yuan and a low of 111.32 yuan during the trading session, with a total transaction amount of 987 million yuan [1] - The company operates in the chemical pharmaceutical sector, focusing on the research and production of high-end generic drugs and innovative drugs [1] Trading Activity - On August 13, a block trade occurred involving 70,000 shares, with a transaction amount of 7.1064 million yuan at a price of 101.52 yuan, which is a 9.99% discount to the closing price of that day [1] - The buyer of this block trade was CITIC Securities Headquarters, while the seller was Guotou Securities Jiangsu Branch [1] - On the same day, the net outflow of main funds was 140 million yuan, while the total net inflow of main funds over the past five days was 333 million yuan [1]

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 进一步统计，近3个月内该股累计发生19笔大宗交易，合计成交金额为1.91亿元。 （文章来源：证券时报网） 两融数据显示，该股最新融资余额为26.04亿元，近5日增加6.70亿元，增幅为34.64%。（数据宝） 8月13日博瑞医药大宗交易一览 博瑞医药8月13日大宗交易平台出现一笔成交，成交量7.00万股，成交金额710.64万元，大宗交易成交价 为101.52元，相对今日收盘价折价9.99%。该笔交易的买方营业部为中信证券股份有限公司总部(非营业 场所)，卖方营业部为国投证券股份有限公司江苏分公司。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | | | | 7.00 | 710.64 | 101.52 | -9.99 | 中信证券股份有限公司总 | 国投证券股份有限公 | | | | | | 部(非营业场所) | 司江苏分公司 | 证券时报·数据宝统计显示，博瑞医药 ...

| 2025-08-13 | 博瑞医药 | 688166 | 101.52 | 710.64 | 中信证券股份有限 Canada controller and | 国投证券股份有限 | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | 公司总部(非营业 | 卖出营业部 公司江苏分公司 | 8月13日，博瑞医药大宗交易成交7万股，成交额710.64万元，占当日总成交额的0.72%，成交价101.52元，较市场收盘价112.79元折价9.99%。 ...